NYSE:GSK
GlaxoSmithKline PLC (GSK)
Financials 
Technical Analysis 
Sep 7, 2026, 12:00 amThis summary was created by AI, based on 4 opinions in the last 12 months.
GlaxoSmithKline PLC (GSK) is highlighted as a top investment pick by Stockchase Research Editor Michael O'Reilly, demonstrating resilience in the healthcare sector amidst market volatility. The company's recent earnings growth of 7% is notable, with financial metrics showing it trades at an appealing 11x earnings and 5.6x book value, alongside a robust return on equity (ROE) of 43%. Analysts have targeted a price of $54.31 for GSK, suggesting further upside potential with a recommended stop-loss strategy in light of ongoing disciplined investment practices. With a dividend yield of 3.3%, it continues to attract interest from investors looking for stability and growth potential in the pharmaceutical industry.
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
